Skip to content
AnalystLens

Exelixis Quarterly Report for Q1 Ended Mar 29, 2024

Filing Date
Filed April 30, 2024
Period End
March 29, 2024
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Material agreement8-K · Dec ’19Dec ’19
  3. Leadership change8-K · May ’22May ’22
  4. Leadership change8-K · May ’26May ’26

Summary

Summary of the 10-Q filed April 30, 2024. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. reported total revenues of $425.2 milliona for the first quarter of 2024, up from $408.8 million in the prior-year quarter, with net product revenues of $378.5 million, up from $363.4 million.

CABOMETYX accounted for $376.4 millionb of net product revenues. Net income was $37.3 million, or $0.12 per share basic and diluted, compared with $40.0 million, or $0.12 per share, a year earlier. The quarter included $32.8 million of restructuring expenses tied to the 2024 Restructuring Plan, which is intended to reduce the workforce and rebalance the cost structure.

Research and development expenses fell to $227.7 millionc from $234.2 million, and selling, general and administrative expenses fell to $114.0 million from $131.4 million. Cash, cash equivalents and investments totaled $1.6 billion at March 31, 2024, compared with $1.7 billion at December 31, 2023. Net cash provided by operating activities was $68.8 million, down from $84.4 million, and the company paid $185.4 million to repurchase common stock.

Under a stock repurchase program authorized in January 2024 for up to $450 milliond before the end of 2024, the company repurchased 8.6 million shares for an aggregate $190.7 million, leaving approximately $259.3 million available. Total stockholders' equity declined to $2.13 billion from $2.26 billion, and the accumulated deficit increased to $258.9 million. The filing highlights ongoing patent litigation over CABOMETYX.

A bench trial in the MSN II case occurred in October 2023, with a judgment expected during the first half of 2024. On March 27, 2024, Cipla amended its ANDA to add further Paragraph IV certifications, which the company is evaluating.

The filing states that any generic CABOMETYX approved and launched before patent expiration could significantly decrease U.S. revenues. The company also disclosed a settlement with Teva that grants Teva a license to market a generic CABOMETYX in the U.S. beginning January 1, 2031, if approved by the FDA.

Key Highlights

  1. Total revenues rose 4% to $425.2 million, with net product revenues of $378.5 million and CABOMETYX contributing $376.4 million.
  2. Net income was $37.3 million, or $0.12 per share, compared with $40.0 million, or $0.12 per share, in the prior-year quarter.
  3. Restructuring expenses of $32.8 million were recorded under the 2024 Restructuring Plan, including the exit of two leases in the Greater Philadelphia area and termination of certain in-licensing arrangements.
  4. Research and development expenses decreased to $227.7 million from $234.2 million, and SG&A decreased to $114.0 million from $131.4 million.
  5. Cash, cash equivalents and investments were $1.6 billion at March 31, 2024, and operating cash flow was $68.8 million.
  6. The company repurchased 8.6 million shares for $190.7 million under a $450 million program, with approximately $259.3 million remaining.
  7. Patent litigation remains a key risk: a judgment in the MSN II case is expected in the first half of 2024, and Cipla amended its ANDA on March 27, 2024 with additional Paragraph IV certifications.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2025, Exelixis kept $0.09.

  1. Revenue$425.2M100.0%
  2. Cost of revenue−$21.3M5.0%
  3. Gross profit$404.0M95.0%
  4. Operating costs−$374.5M88.1%
  5. Operating income$29.5M6.9%
  6. Interest, other & tax$7.9M1.8%
  7. Net income$37.3M8.8%
Computed from 10-QQ1 FY2025filed April 30, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2025 against Q1 FY2024

Line itemQ1 FY2025Q1 FY2024Change
Revenue$425.23M$408.79M+4.0%
Cost of Revenue$21.26M$14.31M+48.5%
Gross Profit$403.97M$394.47M+2.4%
R&D Expenses$227.69M$234.25M−2.8%
SG&A Expenses$113.98M$131.40M−13.3%
Operating Expenses$395.76M$379.96M+4.2%
Operating Income$29.46M$28.83M+2.2%
Net Income$37.32M$40.03M−6.8%
EPS (Basic)$0.12$0.120.0%
EPS (Diluted)$0.12$0.120.0%
Shares Outstanding (Basic)300.76M324.42M−7.3%
Shares Outstanding (Diluted)305.53M326.28M−6.4%

Frequently Asked Questions

  1. How did Exelixis perform financially in the first quarter of 2024?

    Total revenues were $425.2 million, up from $408.8 million, and net income was $37.3 million, or $0.12 per share, compared with $40.0 million, or $0.12 per share, in the first quarter of 2023. Income from operations was $29.5 million, which includes $32.8 million of restructuring expenses.

  2. What is the 2024 Restructuring Plan?

    The Board authorized a corporate restructuring plan to reduce the workforce and rebalance the cost structure in line with strategic priorities, including reducing real estate commitments and terminating certain licensing partnerships. The company recognized $32.8 million of expenses in the quarter and expects the plan to be substantially complete by the end of the second quarter of 2024.

  3. How much cash does Exelixis have, and how is it returning capital to shareholders?

    Cash, cash equivalents and investments were $1.6 billion at March 31, 2024, compared with $1.7 billion at December 31, 2023. The company paid $185.4 million for stock repurchases in the quarter under a program authorized for up to $450 million before the end of 2024, with approximately $259.3 million remaining.

  4. What legal and competitive risks does the filing describe for CABOMETYX?

    The filing describes Paragraph IV patent litigation with MSN, Teva, and Cipla over generic versions of CABOMETYX. A judgment in the MSN II case is expected in the first half of 2024. Cipla amended its ANDA on March 27, 2024 to add certifications for 20 mg and 40 mg strengths. The company states that an early generic launch could significantly decrease U.S. CABOMETYX revenues. Under a settlement with Teva, Teva will be licensed to market a generic version beginning January 1, 2031, if approved by the FDA.

  5. What is the outlook for CABOMETYX sales and operating expenses?

    The company projects net product revenues may increase for the remainder of 2024 compared with the prior-year period, driven by refills from the nivolumab combination and market share gains. It also expects research and development and selling, general and administrative expenses may decrease, reflecting the restructuring, while clinical trial costs may increase for zanzalintinib, XB002, and XL309.